Cover Image
市場調查報告書

惡性肋膜間質細胞瘤:開發中產品分析

Malignant Pleural Mesothelioma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 247800
出版日期 內容資訊 英文 315 Pages
訂單完成後即時交付
價格
Back to Top
惡性肋膜間質細胞瘤:開發中產品分析 Malignant Pleural Mesothelioma - Pipeline Review, H2 2016
出版日期: 2016年11月23日 內容資訊: 英文 315 Pages
簡介

本報告提供惡性肋膜間質細胞瘤的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,再加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

惡性肋膜間質細胞瘤概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

惡性肋膜間質細胞瘤:企業開發中的治療藥

惡性肋膜間質細胞瘤:大學/機關研究中的治療藥

惡性肋膜間質細胞瘤:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

惡性肋膜間質細胞瘤:企業開發中的產品

惡性肋膜間質細胞瘤:大學/機關研究中的產品

惡性肋膜間質細胞瘤的治療藥的開發企業

  • Aduro BioTech, Inc.
  • Advantagene, Inc.
  • Amphera BV
  • AnGes MG, Inc.
  • ArQule, Inc.
  • Bayer AG
  • Biogen, Inc.
  • Bionomics Limited
  • Biotecnol, Inc.
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • CanBas Co., Ltd.
  • Concordia Healthcare Corp.
  • Eli Lilly and Company
  • EnGeneIC Ltd
  • F. Hoffmann-La Roche Ltd.
  • Five Prime Therapeutics, Inc.
  • Genelux Corporation
  • GlaxoSmithKline Plc
  • Juno Therapeutics Inc.
  • Merck & Co., Inc.
  • Millennium Pharmaceuticals, Inc.
  • MolMed S.p.A.
  • Morphotek, Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Oxford BioMedica Plc
  • Pfizer Inc.
  • Pharma Mar, S.A.
  • Polaris Pharmaceuticals, Inc.
  • Sellas Inc.
  • Synta Pharmaceuticals Corp.
  • VasGene Therapeutics, Inc.
  • Verastem, Inc.
  • Virttu Biologics Limited
  • Vyriad

惡性肋膜間質細胞瘤:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

惡性肋膜間質細胞瘤:最近的開發平台趨勢

惡性肋膜間質細胞瘤:暫停中的計劃

惡性肋膜間質細胞瘤:開發中止的產品

惡性肋膜間質細胞瘤:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8690IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Pleural Mesothelioma - Pipeline Review, H2 2016, provides an overview of the Malignant Pleural Mesothelioma (Oncology) pipeline landscape.

Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result, symptoms often include abdominal pain, weight loss, nausea, and vomiting. Other symptoms include anemia, bowel obstructions, chest pain and hemoptysis.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malignant Pleural Mesothelioma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Malignant Pleural Mesothelioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malignant Pleural Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Pleural Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 25, 11 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 4 and 2 molecules, respectively.Malignant Pleural Mesothelioma.

Malignant Pleural Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Pleural Mesothelioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Malignant Pleural Mesothelioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Malignant Pleural Mesothelioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Malignant Pleural Mesothelioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Pleural Mesothelioma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Malignant Pleural Mesothelioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Malignant Pleural Mesothelioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Malignant Pleural Mesothelioma Overview
  • Therapeutics Development
    • Pipeline Products for Malignant Pleural Mesothelioma - Overview
    • Pipeline Products for Malignant Pleural Mesothelioma - Comparative Analysis
  • Malignant Pleural Mesothelioma - Therapeutics under Development by Companies
  • Malignant Pleural Mesothelioma - Therapeutics under Investigation by Universities/Institutes
  • Malignant Pleural Mesothelioma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Malignant Pleural Mesothelioma - Products under Development by Companies
  • Malignant Pleural Mesothelioma - Products under Investigation by Universities/Institutes
  • Malignant Pleural Mesothelioma - Companies Involved in Therapeutics Development
    • Advantagene, Inc.
    • Amphera BV
    • AnGes MG, Inc.
    • ArQule, Inc.
    • Bayer AG
    • Biogen Inc
    • Bionomics Limited
    • Biotecnol Limited
    • Boehringer Ingelheim GmbH
    • Boston Biomedical, Inc.
    • Bristol-Myers Squibb Company
    • CanBas Co., Ltd.
    • Concordia International Corp
    • Eli Lilly and Company
    • EnGeneIC Ltd
    • F. Hoffmann-La Roche Ltd.
    • Genelux Corporation
    • GlaxoSmithKline Plc
    • Juno Therapeutics Inc.
    • MedImmune LLC
    • Merck & Co., Inc.
    • Millennium Pharmaceuticals Inc
    • MolMed S.p.A.
    • Morphotek, Inc.
    • Novartis AG
    • Ono Pharmaceutical Co., Ltd.
    • Oxford BioMedica Plc
    • Pharma Mar, S.A.
    • Polaris Pharmaceuticals, Inc.
    • Sellas Inc
    • Targovax ASA
    • VasGene Therapeutics, Inc.
    • Verastem, Inc.
    • Virttu Biologics Limited
    • Vyriad Inc
  • Malignant Pleural Mesothelioma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • alisertib - Drug Profile
    • amatuximab - Drug Profile
    • anetumab ravtansine - Drug Profile
    • bevacizumab - Drug Profile
    • BG-00001 - Drug Profile
    • BMS-986148 - Drug Profile
    • BNC-105 - Drug Profile
    • CBP-501 - Drug Profile
    • Cellular Immunotherapy for Malignant Pleural Mesothelioma and Advanced Leukemia - Drug Profile
    • Cellular Immunotherapy to Target Mesothelin for Oncology - Drug Profile
    • Cellular Immunotherapy to Target WT1 for Oncology - Drug Profile
    • CSG-MESO - Drug Profile
    • defactinib hydrochloride - Drug Profile
    • durvalumab - Drug Profile
    • durvalumab + tremelimumab - Drug Profile
    • galinpepimut-S - Drug Profile
    • ganetespib - Drug Profile
    • GEN-0101 - Drug Profile
    • Gene Therapy for Malignant Pleural Mesothelioma - Drug Profile
    • Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - Drug Profile
    • GLONC-1 - Drug Profile
    • GSK-2256098 - Drug Profile
    • HSV-1716 - Drug Profile
    • iCasp9M28z - Drug Profile
    • JTCR-016 - Drug Profile
    • LY-3023414 - Drug Profile
    • MesoCancerVac - Drug Profile
    • MesoCART - Drug Profile
    • Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile
    • MTG-201 - Drug Profile
    • napabucasin - Drug Profile
    • NGR-hTNF - Drug Profile
    • nintedanib - Drug Profile
    • nivolumab - Drug Profile
    • Oncolytic Virus for Malignant Pleural Mesothelioma - Drug Profile
    • Oncolytic Virus to Target CD46 for Malignant Pleural Mesothelioma - Drug Profile
    • ONCOS-102 - Drug Profile
    • OXB-301 - Drug Profile
    • pegargiminase - Drug Profile
    • pembrolizumab - Drug Profile
    • porfimer sodium - Drug Profile
    • rAd-IFN - Drug Profile
    • S-588210 - Drug Profile
    • Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Mestatic Lung Cancer - Drug Profile
    • TargomiRs - Drug Profile
    • TB-535 - Drug Profile
    • tivantinib - Drug Profile
    • trabectedin - Drug Profile
    • Vas-01 - Drug Profile
    • VS-5584 - Drug Profile
  • Malignant Pleural Mesothelioma - Dormant Projects
  • Malignant Pleural Mesothelioma - Discontinued Products
  • Malignant Pleural Mesothelioma - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Malignant Pleural Mesothelioma, H2 2016
  • Number of Products under Development for Malignant Pleural Mesothelioma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Advantagene, Inc., H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Amphera BV, H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by AnGes MG, Inc., H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by ArQule, Inc., H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Bayer AG, H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Biogen Inc, H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Bionomics Limited, H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Biotecnol Limited, H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Boston Biomedical, Inc., H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by CanBas Co., Ltd., H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Concordia International Corp, H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Eli Lilly and Company, H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by EnGeneIC Ltd, H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Genelux Corporation, H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Juno Therapeutics Inc., H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by MedImmune LLC, H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Merck & Co., Inc., H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by MolMed S.p.A., H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Morphotek, Inc., H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Novartis AG, H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Oxford BioMedica Plc, H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Pharma Mar, S.A., H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Polaris Pharmaceuticals, Inc., H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Sellas Inc, H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Targovax ASA, H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by VasGene Therapeutics, Inc., H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Verastem, Inc., H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Virttu Biologics Limited, H2 2016
  • Malignant Pleural Mesothelioma - Pipeline by Vyriad Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Malignant Pleural Mesothelioma - Dormant Projects, H2 2016
  • Malignant Pleural Mesothelioma - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Malignant Pleural Mesothelioma, H2 2016
  • Number of Products under Development for Malignant Pleural Mesothelioma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top